Strides reported a weak quarter witnessing a de-growth across revenues of 12% YoY to Rs.688cr during Q1FY22 owing to major sector headwinds such as high logistics cost, price erosion and increased competition. US markets saw a decline of -25% due to double digit price erosion, lower prescription rates and elective surgeries. Other regulated markets were at $30m from $35m in Q1FY21 due to lockdowns in the UK leading to supply chain disruptions. Institutional business was subdued by 33% on account of lower take off of TLD in the quarter. However, the African business reported a 4% QoQ growth despite lower demand for acute...